Therapy-related myeloid neoplasms.

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• The 2007 Society for Hematopathology/European Association for Haematopathology workshop addressed therapy-related myeloid neoplasms (t-MNs).
• This review synthesizes current knowledge on the clinical, pathologic, and genetic aspects of t-MNs.
• Focus is placed on understanding the pathogenesis of these treatment-induced malignancies.

Observation:

• Diagnostic challenges include differentiating therapy-related myelodysplastic syndrome (t-MDS) from therapy-related acute erythroid leukemia (t-AEL).
• The World Health Organization classification groups t-MDS and therapy-related acute myeloid leukemia (t-AML) as a single entity.
• Diverse morphologic presentations within t-MNs necessitate careful bone marrow examination.

Findings:

• Bone marrow morphology remains a critical initial diagnostic step.
• Therapy-related acute myeloid leukemias (t-AML) with recurrent cytogenetic abnormalities are presented.
• Accurate classification of t-AML is clinically significant due to its impact on patient outcomes.

Implications:

• Accurate morphologic assessment is vital for patient evaluation and management of t-MNs.
• Understanding distinct subtypes of t-AML with specific cytogenetic abnormalities can guide therapeutic strategies.
• This knowledge aids in refining diagnostic criteria and improving prognostic accuracy for therapy-related malignancies.